Programmes 3 & 4 – Cannabinoid derivatives

Programmes 3 & 4 have significantly advanced as a result of our worldwide exclusive licence from Canopy Growth Corporation which includes 335 cannabinoid derivatives, already available and tested together with 14 patent families.  Both programmes will be advanced in partnership with Dalriada and Oxford StemTech

Programme 3:

• Will be a diversified pCB-derivative with undisclosed indication
• It will have patent protection and/or orphan market exclusivity (7yr US/10yr EU)
• We aim to develop up to the pre-clinical stage by Q2 2023

Programme 4:

• Will be a cannabinoid derivative with a new target for pain and potentially other therapeutic areas
• Initially targeting indications in neuropathic pain (additional indications include epilepsy and cancer)
• We aim to progress to lead candidate by Q2 2023